New drug applications approved by US FDA as of 16 - 31 August 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
New drug applications approved by US FDA as of 1 - 15 May 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
The true prevalence of benign prostatic hyperplasia (BPH) in male populations has been difficult to estimate due to the lack of a standardized definition. However, the characteristic features of BPH – abnormal proliferation of stromal and epithelial prostatic cells – become more common in men with age. The following article highlights the benefits of dutasteride/tamsulosin (Duodart®, GlaxoSmithKline), a combination treatment consisting of two drugs with complementary mechanisms of action, in patients with BPH.
Sleep problems appear to be associated with progression of lower urinary tract symptoms (LUTS) in men with the urologic condition and with LUTS development among asymptomatic men, according to data from the REDUCE* study.
Despite being common, less than half of Singaporean women have sought medical attention for urinary incontinence for fear of surgery, embarrassment and other misconceptions, a new study from Singapore has found
Long-term testosterone replacement therapy (TRT) is beneficial in men with late-onset hypogonadism (LOH) in a study and is even associated with improvement in sexual function and vitality, physical pain, general health, and overall health-related quality of life (HRQoL).
Physiotherapy and behaviour therapy appear to be effective interventions in females with overactive bladder syndrome, with those who have had no previous exposure to the treatments benefitting from post-therapy effects, a recent study has shown.